NSCLC组织CircRNA ADAM22表达与含顺铂化疗方案敏感性的关系  

Relationship between the expression of CircRNA ADAM22 in NSCLC tissues and the sensitivity of cisplatin containing chemotherapy regimens

作　　者：任婷婷 岳文彬 刘月芬 REN Tingting;YUE Wenbin;LIU Yuefen(Department of Oncology,Puyang Oilfield General Hospital,Puyang 457001,China)

机构地区：[1]濮阳油田总医院肿瘤科,河南濮阳457001

出　　处：《东南大学学报（医学版）》2024年第2期216-223,共8页Journal of Southeast University(Medical Science Edition)

摘　　要：目的:探讨非小细胞肺癌(NSCLC)组织环状核糖核酸(CircRNA)去整合素金属蛋白酶22(ADAM22)表达与含顺铂化疗方案敏感性的关系。方法:选取2018年2月至2020年2月在本院接受治疗的103例NSCLC患者为研究对象,均接受含顺铂化疗方案治疗。采用实时荧光定量聚合酶链反应检测肺癌组织与癌旁组织CircRNA ADAM22表达。分析肺癌组织CircRNA ADAM22表达与患者临床病理特征的关系。根据化疗近期疗效,将患者分为化疗有效组和化疗无效组,比较两组肺癌组织CircRNA ADAM22表达;采用Logistic回归模型分析肺癌组织CircRNA ADAM22表达与化疗敏感性的关系;采用Cox比例风险回归模型分析影响患者生存的危险因素,采用Kaplan-Meier法分析肺癌组织CircRNA ADAM22表达与患者3年生存率的关系。结果:肺癌组织CircRNA ADAM22表达量(2.69±0.65)高于癌旁组织(1.47±0.36)(P<0.05);不同性别、年龄、组织学类型、分化程度以及有无吸烟史患者肺癌组织CircRNA ADAM22表达比较差异无统计学意义(P>0.05),而原发肿瘤/区域淋巴结/远处转移(TNM)分期Ⅲ+Ⅳ期、有淋巴结转移患者肺癌组织CircRNA ADAM22高表达占比高于TNM分期Ⅱ期、无淋巴结转移患者(P<0.05)。化疗无效组癌组织CircRNA ADAM22高表达占比高于化疗有效组(P<0.05);多因素Logistic回归分析显示,TNM分期Ⅲ+Ⅳ期、淋巴结转移、肺癌组织CircRNA ADAM22高表达、未联合使用免疫抑制剂均是影响NSCLC患者含顺铂化疗方案敏感性的危险因素(P<0.05)。103例NSCLC患者3年生存率为55.34%;死亡者中癌组织CircRNA ADAM22高表达占比高于生存者(P<0.05);多因素Cox比例风险回归模型分析显示,淋巴结转移、癌组织CircRNA ADAM22高表达、未联合使用免疫抑制剂是NSCLC患者3年死亡的危险因素(P<0.05);根据Kaplan-Meier生存曲线分析,肺癌组织CircRNA ADAM22高表达患者3年生存率低于癌组织CircRNA ADAM22低表达患者(P<0.05)。结论:NSCLC组织�Objective:To explore the relationship between the expression of cyclic RNA(CircRNA)adisintegrin and metalloproteinases 22(ADAM22)in non-small cell lung cancer(NSCLC)tissues and the sensitivity of cisplatin containing chemotherapy regimens.Methods:103 NSCLC patients who received treatment in our hospital from February 2018 to February 2020 were selected as the study subjects,all of whom received cisplatin containing chemotherapy regimens.The expression of CircRNA ADAM22 in lung cancer tissues and adjacent tissues were detected by using real time fluorescence quantitative polymerase chain reaction.The relationship between the expression of CircRNA ADAM22 in lung cancer tissues and the clinicopathological characteristics of patients was analyzed.According to the recent efficacy of chemotherapy,patients were divided into chemotherapy effective group and chemotherapy ineffective group,and the expression of CircRNA ADAM22 in lung cancer tissues was compared between the two groups.The relationship between CircRNA ADAM22 expression in lung cancer tissues and chemotherapy sensitivity was analyzed by using Logistic regression model.The risk factors affecting patient survival was analyzed by using Cox proportional risk regression model.The relationship between the expression of CircRNA ADAM22 in lung cancer tissues and the 3-year survival rate of patients was analyzed by using Kaplan-Meier method.Results:The expression level of CircRNA ADAM22 in lung cancer tissues(2.69±0.65)was higher than that in adjacent tissues(1.47±0.36)(P<0.05).There was no statistically significant difference in the expression of CircRNA ADAM22 in lung cancer tissues between patients of different genders,ages,histological types,degrees of differentiation and smoking history(P>0.05),but the proportions of high expression of CircRNA ADAM22 in lung cancer tissues of patients with tumor node metastasis(TNM)stage Ⅲ+Ⅳ and lymph node metastasis were higher than patients with TNM stageⅡand no lymph node metastasis(P<0.05).The proportion of high expre

关 键 词：非小细胞肺癌 环状核糖核酸 去整合素金属蛋白酶22 顺铂 化疗敏感性 

分 类 号：R734.2[医药卫生—肿瘤]